Asset Details
Do you wish to reserve the book?
1103 Does slow escalation of steroid dose reduce the risk of deterioration in patients with a myasthenic crisis?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
1103 Does slow escalation of steroid dose reduce the risk of deterioration in patients with a myasthenic crisis?
Do you wish to request the book?
1103 Does slow escalation of steroid dose reduce the risk of deterioration in patients with a myasthenic crisis?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
1103 Does slow escalation of steroid dose reduce the risk of deterioration in patients with a myasthenic crisis?
2017
Overview
BackgroundThere is a risk of steroid induced deterioration in patients with exacerbation of myasthenia gravis, possibly reduced if the steroid dose is increased slowly. However, there is limited evidence for this and individual practice varies. We aimed to determine if a slow steroid dose escalation reduced the risk of respiratory failure in our hospital.MethodsWe retrospectively analysed the clinical records of all patients admitted to our hospital with an exacerbation of myasthenia gravis between January 2010 and December 2014.Results69 patients were admitted with an exacerbation of myasthenia gravis. 51 patients were treated with a slowly increasing dose and 18 patients immediately with a high dose of steroids. There was a no significant increase in ITU admission in the high dose group (27.78% vs 17.65% p:0.4957) nor any difference in FVC trend, readmission rate, mortality, or treatment with IVIG or PLEX. Length of stay was longer in the patients treated with a slowly escalating dose of steroids (mean number of days 17.8 vs 15.22, p:0.1687).ConclusionWe did not find a significant deterioration in patients treated with a high dose of steroids. Given most patients are treated with an escalating steroid dose (that requires a longer hospital stay) there is need for a randomised trial to determine if this is required.
Publisher
BMJ Publishing Group LTD
Subject
